Epstein-Barr virus isolates retain their capacity to evade t cell immunity through BNLF2a despite extensive sequence variation

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 572-577

  Horst, Daniëlle ^a   Burrows, Scott R ^b   Gatherer, Derek ^c   Van Wilgenburg, Bonnie ^d,e   Bell, Melissa J ^b   Boer, Ingrid G J ^a   Ressing, Maaike E ^a   Wiertz, Emmanuel J H J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BNLF2A PROTEIN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN; MUTANT PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BNLF2A GENE; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENETIC CONSERVATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; IMMUNE EVASION; MOLECULAR RECOGNITION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; VIRUS GENE; VIRUS ISOLATION; VIRUS VIRULENCE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; EPSTEIN-BARR VIRUS INFECTIONS; EVOLUTION, MOLECULAR; GENETIC VARIATION; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; MOLECULAR SEQUENCE DATA; SELECTION, GENETIC; SEQUENCE ALIGNMENT; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 84855938797     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05151-11     Document Type: Article

References (34)

1. Apolloni A, et al. 1992. Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus. Eur. J. Immunol. 22:183-189.
2. Baer R, et al. 1984. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310:207-211.
3. Bell MJ, et al. 2008. Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response. J. Infect. Dis. 197:1594 -1597.
4. Burrows JM, et al. 2004. Selection pressure-driven evolution of the Epstein-Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia. J. Virol. 78:7131-7137.
5. Burrows JM, et al. 1996. Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J. Virol. 70:2490 -2496.
6. Carrington M, Colonna M, Spies T, Stephens JC, Mann DL. 1993. Haplotypic variation of the transporter associated with antigen processing (TAP) genes and their extension of HLA class II region haplotypes. Immunogenetics 37:266 -273.
7. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. 2009. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res. 143:209 -221.
8. Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T. 1992. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc. Natl. Acad. Sci. U. S. A. 89:3932-3936.
9. Croft NP, et al. 2009. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog. 5:e1000490.
10. Dambaugh T, Hennessy K, Chamnankit L, Kieff E. 1984. U2 region of Epstein-Barr virusDNAmay encode Epstein-Barr nuclear antigen 2. Proc. Natl. Acad. Sci. U. S. A. 81:7632-7636.
11. + population. Science 260:98 -100.
12. de Campos-Lima PO, et al. 1994. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J. Exp. Med. 179:1297-1305.
13. Dolan A, Addison C, Gatherer D, Davison AJ, McGeoch DJ. 2006. The genome of Epstein-Barr virus type 2 strain AG876. Virology 350:164 -170.
14. + T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J. Exp. Med. 204:1863-1873.
15. Horst D, et al. 2011. EBV protein BNLF2a exploits host tail-anchored protein integration machinery to inhibit TAP. J. Immunol. 186: 3594-3605.
16. Horst D, et al. 2009. Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J. Immunol. 182:2313-2324.
17. Hsu DH, et al. 1990. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250:830-832.
18. Kanai K, et al. 2007. The vIL-10 gene of the Epstein-Barr virus (EBV) is conserved in a stable manner except for a few point mutations in various EBV isolates. Virus Genes. 35:563-569.
19. Khanim F, et al. 1997. BHRF1, a viral homologue of the Bcl-2 oncogene, is conserved at both the sequence and functional level in different Epstein-Barr virus isolates. J. Gen. Virol. 78:2987-2999.
20. Momburg F, et al. 1994. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 367:648-651.
21. Neefjes J, et al. 1995. Analysis of the fine specificity of rat, mouse and human TAP peptide transporters. Eur. J. Immunol. 25:1133-1136.
22. Powis SH, et al. 1992. Polymorphism in a second ABC transporter gene located within the class II region of the human major histocompatibility complex. Proc. Natl. Acad. Sci. U. S. A. 89:1463-1467.
23. Powis SH, et al. 1993. Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2. Immunogenetics 37:373-380.
24. + T cell immunity via concerted actions of multiple gene products. Semin. Cancer Biol. 18:397- 408.
25. Rickinson AB, Kieff E. 2007. Epstein-Barr Virus, p 2655-2700. In D. M. Knipe et al (ed), Fields virology, vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
26. + T cell immunity. Microbes Infect. 12:173-181.
27. Sample J, et al. 1990. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J. Virol. 64:4084-4092.
28. Uebel S, et al. 1997. Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. Proc. Natl. Acad. Sci. U. S. A. 94:8976-8981.
29. van Endert PM, Lopez MT, Patel SD, Monaco JJ, McDevitt HO. 1992. Genomic polymorphism, recombination, and linkage disequilibrium in human major histocompatibility complex-encoded antigen-processing genes. Proc. Natl. Acad. Sci. U. S. A. 89:11594 -11597.
30. van Endert PM, et al. 1995. The peptide-binding motif for the human transporter associated with antigen processing. J. Exp. Med. 182: 1883-1895.
31. van Ham SM, et al. 1997. HLA-DO is a negative modulator of HLA-DMmediated MHC class II peptide loading. Curr. Biol. 7:950 -957.
32. Vellinga J, Uil TG, de Vrij J, Rabelink MJ, Lindholm L, Hoeben RC. 2006. A system for efficient generation of adenovirus protein IXproducing helper cell lines. J. Gene Med. 8:147-154.
33. Yang Z. 2007. PAML 4: phylogenetic analysis by maximum likelihood. Mol. Biol. Evol. 24:1586 -1591.
34. Zeng MS, et al. 2005. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J. Virol. 79: 15323-15330.